Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LY4170156 |
| Trade Name | |
| Synonyms | LY-4170156|LY 4170156 |
| Drug Descriptions |
LY4170156 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against FOLR1 (folate receptor alpha; FRa) linked to the topoisomerase I inhibitor exatecan, which may induce apoptosis and inhibit proliferation of tumor cells expressing FOLR1 (FRa) (J Clin Oncol (2024) 42:16_suppl, 3023, NCI Drug Dictionary). |
| DrugClasses | FOLR1-targeted Therapy 24 |
| CAS Registry Number | NA |
| NCIT ID | C207085 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + LY4170156 | Bevacizumab LY4170156 | 0 | 2 |
| Carboplatin + LY4170156 | Carboplatin LY4170156 | 0 | 1 |
| Itraconazole + LY4170156 | Itraconazole LY4170156 | 0 | 1 |
| LY4170156 | LY4170156 | 0 | 2 |
| LY4170156 + Pembrolizumab | LY4170156 Pembrolizumab | 0 | 1 |